cerebrovascular disease
Conditions
Interventions
Edaravone dexborneol: edaravone dexborneol intravenous infusion of 37.5 mg/dose (edaravone, 30 mg
(+)-borneol, 7.5 mg), once every
12 hours, and the treatment continued for 14 days.
Edaravone :the same treatment excluding (+)-borneol.
Sponsors
Chongqing University Jiangjin Hospital(Jiangjin Central Hospital of Chongqing)
Eligibility
Sex/Gender
All
Age
35 Years to 80 Years
Inclusion criteria
Inclusion criteria: age 35–80years, with definite signs and symptoms of nervous system localization, diagnosis of AIS, ability to start the study drug within 72hours after stroke onset, a National Institutes of Health Stroke Scale (NIHSS) score between 4 and 24, Without intravenous thrombolysis or intravascular therapy, Head CT ruled out cerebral hemorrhage.
Exclusion criteria
Exclusion criteria: DWI showed no acute cerebral infarction; Cerebrovascular accident occurred within 3 months; Severe shock and failure to respond to pressor dilatation therapy; Patients with severe hepatic and renal insufficiency; Patients with malignant tumors; Other combined medical history that may affect the determination of endpoint events and follow-up, such as history of traumatic brain injury, multiple sclerosis, encephalitis, tumors, poisoning, syphilis, etc. Patients with MRI contraindications or non-cooperation; Refused to sign the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ktrans Value;Ki/c; | — |
Secondary
| Measure | Time frame |
|---|---|
| infarct volume; | — |
Countries
China
Contacts
Public ContactZuowen Zhang
Chongqing University Jiangjin Hospital(Jiangjin Central Hospital of Chongqing)
Outcome results
None listed